Table 3.
Summative outcomes by group at each follow-up.
| Control (n = 37) | Telephone (n = 38) | Mobile App (n = 36) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 Months | 6 Months | 12 Months | 3 Months | 6 Months | 12 Months | 3 Months | 6 Months | 12 Months | |
| QALY—mean (sd) | - | - | 0.55 (0.28) | - | - | 0.57 (0.28) | - | - | 0.59 (0.23) |
| Mortality prior to this follow-up—n (cumulative %) | 4 (11%) | 3 (19%) | 4 (30%) | 2 (5%) | 4 (16%) | 6 (33%) | 1 (3%) | 1 (6%) | 6 (22%) |
| n (% relative to baseline) # | n = 30 (81%) | n = 28 (76%) | n = 30 (81%) | n = 33 (87%) | n = 34 (89%) | n = 34 (89%) | n = 28 (78%) | n = 29 (80%) | n = 28 (78%) |
| EQ-5D-5L utility score—mean (sd) | 0.54 (0.37) | 0.52 (0.35) | 0.48 (0.42) | 0.65 (0.29) | 0.60 (0.35) | 0.45 (0.41) | 0.62 (0.30) | 0.60 (0.32) | 0.42 (0.39) |
| EQ-5D-5L visual analogue scale—mean (sd) | 56.8 (29.9) | 53.2 (35.6) | 48.1 (41.5) | 64.5 (24.1) | 59.1 (32.8) | 47.6 (41.4) | 63.3 (26.4) | 60.8 (30.2) | 48.9 (41.6) |
| n (% relative to baseline) * | n = 26 (70%) | n = 20 (54%) | n = 18 (49%) | n = 32 (84%) | n = 28 (74%) | n = 21 (55%) | n = 26 (72%) | n = 25 (69%) | n = 17 (47%) |
| EQ-5D-5L—median (IQR) | |||||||||
| Mobility | 1.5 (1, 2) | 1 (1, 2) | 1 (1, 1) | 1 (1, 2.5) | 1 (1, 2.5) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 2 (1, 2) |
| Personal care | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 1 (1, 2) |
| Usual activities | 2 (1, 3) | 1 (1, 2) | 1 (1, 1) | 1.5 (1, 3) | 1.5 (1, 2) | 1 (1, 2) | 1.5 (1, 3) | 1 (1, 2) | 2 (1, 2) |
| Pain or discomfort | 2 (1, 2) | 2 (1, 2) | 1.5 (1, 2) | 2 (1, 3) | 1 (1, 3) | 2 (1, 2) | 1 (1, 2) | 2 (1, 2) | 1 (1, 2) |
| Anxiety or depression | 2 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) |
| Weight (kg)—mean (sd) | 75.6 (20.3) | 75.6 (17.5) | 73.2 (18.4) | 71.7 (11.8) | 70.2 (11.7) | 68.6 (13.3) | 71.7 (15.6) | 68.7 (14.1) | 68.5 (14.1) |
| PG-SGASF score—mean (sd) | 7.5 (5.0) | 4.6 (3.6) | 4.1 (4.1) | 7.8 (5.7) | 6.2 (5.1) | 4.3 (4.7) | 8.4 (6.1) a | 7.2 (4.0) | 4.9 (3.6) |
| EORTC QLQ-C30 score—mean (sd) | |||||||||
| Global health | 54.3 (25.1) | 69.8 (12.2) | 72.7 (15.9) | 66.4 (19.7) b | 68.0 (28.13) | 74.8 (23.8) | 62.3 (24.5) | 59.25 (21.10) | 73.5 (20.5) |
| Physical functioning | 70.8 (26.0) | 81.3 (14.1) | 86.7 (15.5) | 74.0 (18.5) | 75.95 (21.72) | 80.6 (20.0) | 73.8 (26.8) | 73.33 (17.32) | 82.7 (16.3) |
| Role functioning | 48.7 (31.9) | 71.7 (25.4) | 78.7 (25.4) | 62.0 (32.9) | 68.45 (32.18) | 75.4 (34.0) | 59.6 (35.3) | 54.67 (25.24) | 77.4 (16.7) |
| Emotional functioning | 72.8 (24.8) | 80.8 (16.7) | 85.6 (11.4) | 82.6 (18.7) | 80.65 (22.23) | 84.1 (15.1) | 76.3 (22.40) | 73.33 (22.31) | 83.8 (17.8) |
| Cognitive functioning | 72.4 (26.6) | 80.0 (17.6) | 82.4 (16.6) | 82.8 (19.0) | 83.93 (21.98) | 85.7 (20.6) | 78.7 (24.8) | 80 (20.41) | 82.4 (21.6) |
| Social functioning | 58.3 (41.7) | 80.0 (20.7) | 82.4 (27.7) | 71.5 (30.2) | 76.79 (25.0) | 84.1 (26.1) | 74.0 (32.3) | 66.6 (26.8) | 87.2 (21.7) |
| Fatigue | 54.7 (26.6) | 37.2 (22.0) | 25.3 (22.5) | 42.9 (23.5) | 39.28 (23.7) | 33.3 (24.3) | 45.7 (26.2) | 45.8 (26.3) | 34.0 (26.5) |
| Nausea and vomiting | 14.1 (16.1) | 8.3 (14.8) | 11.1 (21.4) | 7.8 (15.8) | 9.5 (12.4) | 7.1 (11.3) | 9.6 (14.8) | 6.0 (9.5) | 8.8 (19.6) |
| Pain | 29.5 (32.1) | 29.2 (24.7) | 22.2 (23.6) | 22.4 (30.1) | 25.0 (30.6) | 22.2 (22.0) | 20.5 (29.9) | 16.0 (21.2) | 18.6 (15.5) |
| Dyspnoea | 19.2 (30.1) | 11.7 (19.6) | 14.8 (23.5) | 21.9 (24.8) | 19.0 (24.7) | 23.8 (28.2) | 21.8 (23.0) | 18.7 (23.7) | 15.7 (23.9) |
| Insomnia | 35.9 (35.2) | 28.3 (29.2) | 25.9 (21.6) | 29.2 (37.6) | 22.6 (27.3) | 25.0 (30.3) | 34.6 (40.5) | 32.0 (31.1) | 31.4 (34.3) |
| Appetite loss | 38.5 (33.6) | 20 (27.4) | 14.8 (23.5) | 32.3 (28.7) | 23.8 (29.9) | 20.6 (26.8) | 35.9 (38.8) | 26.7 (25.5) | 25.5 (32.3) |
| Constipation | 16.7 (30.2) | 11.7 (24.8) | 9.3 (22.3) | 12.5 (22.0) | 17.9 (23.1) | 12.7 (19.6) | 19.2 (34.2) | 13.3 (25.6) | 7.8 (18.7) |
| Diarrhoea | 23.1 (32.3) | 18.3 (22.9) | 22.2 (30.2) | 19.3 (29.5) | 20.2 (27.7) | 19.0 (29.0) | 18.7 (27.5) | 22.7 (31.5) | 15.7 (24.0) |
| Financial difficulties | 21.8 (33.9) | 13.3 (29.4) | 13.0 (23.3) | 8.6 (19.2) | 9.5 (23.8) | 17.5 (34.3) | 19.3 (34.0) | 20.7 (33.8) | 19.6 (37.4) |
# Sample size decreased due to withdrawal or lost to follow up. * Sample size decreased due to participant death, withdrawal, or lost to follow up. a n = 25; b n = 31; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30; PG-SGASF, Patient-Generated Subjective Global Assessment Short Form.